Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 15, Issue 17, 1999, Pages 1563-1571

  Dreyer, Kimberly ^a   Kallas, Esper G ^a,b   Planelles, Vicente ^a   Montefiori, David ^c   McDermott, Michael P ^a   Hasan, Muhammad S ^a   Evans, Thomas G ^a,d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS TITRATION;

ANTI-HIV AGENTS; ANTIBODY SPECIFICITY; ANTIGENS, CD4; CELL LINE; COHORT STUDIES; GREEN FLUORESCENT PROTEINS; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; IMMUNOGLOBULIN G; LUMINESCENT PROTEINS; NEUTRALIZATION TESTS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; SPECIES SPECIFICITY;

EID: 0033589705     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299309856     Document Type: Article

References (36)

1. Detels R, Munoz A, McFarlane G, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-1503.
2. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116. [See comments].
3. Autran B, Carcelaint G, Li TS, et al: Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999;66: 207-211. [In Process Citation].
4. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, and Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686. [See comments]
5. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, and Hanson CV: Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-219.
6. Montefiori DC, Pantaleo G, Fink LM, et al: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173: 60-67.
7. Pilgrim AK, Pantaleo G, Cohen OJ, et al: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:924-932.
8. Zhang YJ, Fredriksson R, McKeating JA, and Fenyö EM: Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 1997;238:254-264.
9. Hioe CE, Xu S, Chigurupati P, et al: Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol 1997;9:1281-1290.
10. Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, and Wasi C: Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env genetic subtype B and E viruses in Thailand. Viral Immunol 1996;9:175-185.
11. Moog C, Spenlehauer C, Fleury H, et al: Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neutralization in vivo. AIDS Res Hum Retroviruses 1997;13:19-27.
12. Cao Y, Qin L, Zhang L, Safrit J, and Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332: 201-208. [See comments].
13. Burton DR and Montefiori DC: The antibody response in HIV-1 infection. AIDS 1997;11(Suppl. A):S87-98. [See comments].
14. Montefiori DC and Evans TG: Toward an HIV-1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses 1999;15:689-698.
15. Reitter JN, Means RE, and Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nature Med 1998;4:679-684.
16. Sattentau QJ: Neutralization of HIV-1 by antibody. Curr Opin Immunol 1996;8:540-545.
17. Poignard P, Klasse PJ, and Sattentau QJ: Antibody neutralization of HIV-1. Immunol Today 1996;17:239-246.
18. Mascola JR, Snyder SW, Weislow OS, et al: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-348.
19. Belshe RB, Graham BS, Keefer MC, et al: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994;272:475-480. [See comments].
20. VanCott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
21. Morris L, Binley JM, Clas BA, et al.: HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188;233-245.
22. Cecilia D, KewalRamani VN, O'Leary J, et al.: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72:6988-6996.
23. Trkola A, Ketas T, Kewalramani VN, et al.: Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998;72:1876-1885.
24. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
25. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, and Chen IS: Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987;236:819-822.
26. O'Brien WA, Koyanagi Y, Namazie A, et al.: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (London) 1990;348: 69-73.
27. Haigwood NL, Watson A, Sutton WF, et al.: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol Lett 1996;51:107-114.
28. Clements JE, Montelaro RC, Zink MC, et al.: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
29. Foresman L, Jia F, Li Z, et al.: Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 1998;14:1035-1043.
30. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infection of macaque monkeys. Nature Med 1999;5:204-210. [In Process Citation].
31. Mascola JR, Lewis MG, Stigler G, et al.: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73: 4009-4018. [In Process Citation].
32. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, and Nunberg JH: Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999;283:357-362. [See comments].
33. Moog C, Fleury HJ, Pellegrin I, Kirn A, and Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-3741.
34. Carotenuto P, Looij D, Keldermans L, de Wolf F, and Goudsmit J: Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12:1591-1600.
35. Montefiori DC, Collman RG, Fouts TR, et al.: Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998;72:1886-1893.
36. LaCasse RA, Follis KE, Moudgil T, et al.: Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitiyity. J Virol 1998;72:2491-2495.